Breaking News

Biovian Invests €50M in Manufacturing Facility in Finland

New facility will support the development, manufacturing, and testing of advanced therapy medicinal products.

Biovian, a CDMO specializing in biopharmaceuticals, is investing over €50 million to expand its manufacturing facility in Turku, Finland to meet growing demand for innovative biologics and gene therapies. The new 69,000 square foot facility will house cutting-edge equipment and advanced technologies to support the development, manufacturing, and testing of advanced therapy medicinal products (ATMPs), such as adenoviral and AAV (adeno-associated viral) therapies. It will also feature dedicated...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters